On October 9, 2023, MolDx will hold an open comment meeting on several recently announced LCDs or revisions - thyroid, lung, and prostate.
See the general page here and click on the October 9 meeting.
https://www.palmettogba.com/palmetto/jjb.nsf/DID/B7ML2U1021
Here's the October 9 agenda:
Open Meeting Notification — Proposed LCD(s) Released for Comment
- MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules DL39646
- MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy DL39654
- MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers DL39636
Dates and Durations: MolDxOlogy
The Thyroid LCD is based on a request letter, 1/12/2022. The pulmonary nodule LCD was "MAC initiated." The prostate LCD is based on a 2/1/2022 letter.
Where data is available, the lag between an LCD request and a proposed LCD is about 18 months. Then, the lag to a final LCD is usually, generally, about 12 months more, for a total of 30 months or 2.5 years from letter to coverage date.
##
MolDx held a 9/18 meeting on its donor DNA transplant management policy; that transcript is not up yet.
